Business Description
Indaptus Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US45339J2042
Total Employee Number:
5Description
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 166.44 | |||||
Equity-to-Asset | 0.57 | |||||
Debt-to-Equity | 0.01 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 25.9 | |||||
3-Year EPS without NRI Growth Rate | 23.6 | |||||
3-Year FCF Growth Rate | 29.8 | |||||
3-Year Book Growth Rate | -74 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 40.26 | |||||
9-Day RSI | 41.47 | |||||
14-Day RSI | 45.16 | |||||
3-1 Month Momentum % | 10.17 | |||||
6-1 Month Momentum % | 47.17 | |||||
12-1 Month Momentum % | -64.22 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.34 | |||||
Quick Ratio | 2.34 | |||||
Cash Ratio | 1.61 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -93.3 | |||||
Shareholder Yield % | -1.8 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -930.47 | |||||
ROA % | -308.3 | |||||
ROIC % | -716.03 | |||||
3-Year ROIIC % | -257.75 | |||||
ROC (Joel Greenblatt) % | -38287.91 | |||||
ROCE % | -859.79 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 252 | |||||
Price-to-Tangible-Book | 252 | |||||
EV-to-EBIT | -18.94 | |||||
EV-to-EBITDA | -18.94 | |||||
EV-to-FCF | -19.66 | |||||
| Price-to-Net-Current-Asset-Value | 253 | |||||
Earnings Yield (Greenblatt) % | -5.28 | |||||
FCF Yield % | -5 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:INDP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Indaptus Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -16.043 | ||
| Beta | 0.7631 | ||
| 3-Year Sharpe Ratio | -0.7 | ||
| 3-Year Sortino Ratio | -0.96 | ||
| Volatility % | 126.65 | ||
| 14-Day RSI | 45.16 | ||
| 14-Day ATR ($) | 0.374234 | ||
| 20-Day SMA ($) | 2.8595 | ||
| 12-1 Month Momentum % | -64.22 | ||
| 52-Week Range ($) | 0.92 - 10.9109 | ||
| Shares Outstanding (Mil) | 133.24 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Indaptus Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Indaptus Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 113 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 22 days | ||
| General meeting for 2026 | 2026-07-28 10:00 | In 7 days | ||
| First quarter earnings results for 2026 | 2026-05-15 | 1.75 (+0.00%) | ||
| Annual report for 2025 | 2026-03-17 | 1.75 (-2.23%) | ||
| Third quarter earnings results for 2025 | 2025-11-12 | 2.72 (-0.37%) | ||
| H.C. Wainwright 27th Annual Global Investment Conference | 2025-09-08 15:30 | 3.30 (-17.43%) | ||
| Second quarter earnings results for 2025 | 2025-08-13 | 8.24 (-3.06%) | ||
| 0.0357143:1 Stock Split | 2025-06-27 | 12.85 (+27.67%) | ||
| General meeting for 2025 | 2025-06-10 10:00 | 9.59 (-2.11%) |
Show
Entries
Indaptus Therapeutics Inc Frequently Asked Questions
What is Indaptus Therapeutics Inc(INDP)'s stock price today?
The current price of INDP is $2.52. The 52 week high of INDP is $10.91 and 52 week low is $0.92.
When is next earnings date of Indaptus Therapeutics Inc(INDP)?
The next earnings date of Indaptus Therapeutics Inc(INDP) is 2026-08-13 Est..
Does Indaptus Therapeutics Inc(INDP) pay dividends? If so, how much?
Indaptus Therapeutics Inc(INDP) does not pay dividend.
Guru Commentaries on NAS:INDP
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Indaptus Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers